Olmesartán Pensa Pharma (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Olmesartán Pensa Pharma, is a Angiotensin II receptor blocker presented as an oral tablet for oral use. It treats hypertension by lowering elevated blood pressure in adult patients.

GNH USA supplies Olmesartán Pensa Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil belongs to the Angiotensin II receptor blocker class and is used to manage conditions related to the renin‑angiotensin system. - Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension. - Hypertensive heart disease: helps control blood pressure to lessen cardiac workload. - Diabetes‑related hypertension: assists in achieving target blood pressure in patients with both diabetes and hypertension.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general tiredness without exertion. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat. - Hyperkalemia: elevated potassium levels in blood. - Acute renal impairment: sudden decrease in kidney function. - Hepatic injury: abnormal liver enzyme elevations.

Olmesartan should be used with careful clinical monitoring and patient education. - Blood pressure monitoring: check regularly to avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium: monitor especially if combined with potassium‑sparing agents. - Pregnancy: contraindicated in pregnancy due to fetal toxicity risk. - Elderly patients: start at lower dose and monitor for orthostatic effects. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan may interact with several medicines that affect blood pressure or renal function. Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal dysfunction. - Dual therapy with ACE inhibitors or other ARBs: heightened risk of hyperkalemia and renal impairment. - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. Moderate Interactions (Monitor Closely): - Thiazide diuretics: additive hypotensive effect, monitor blood pressure. - Lithium: possible increase in lithium levels, watch for toxicity. - Cyclosporine: may raise olmesartan plasma concentrations, assess renal function.